ClinicalTrials.gg
RecruitingNCT07187219NeuroCanPainUpdated Sep 22, 2025

Efficacy of Repetitive Transcranial Magnetic Stimulation Over the Primary Cortex in Patients With Neuropathic Pain and Cancer

An interventional study of Repetitive transcranial magnetic stimulation (rTMS) - active and Repetitive transcranial magnetic stimulation (rTMS) - inactive in Cancer and Chronic Neuropathic Pain, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

High-frequency repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex (M1) has shown its efficacy to alleviate pain in patients suffering from refractory neuropathic pain. rTMS is now considered as 3rd-line therapy (by the French Society for the Study and Treatment of Pain) for patient's refractory to drug therapy.

However, its efficacy in chronic neuropathic pain related to cancer has not yet been specifically studied, and it therefore remains relatively inaccessible for these patients. This project is a cross-over, double-blinded, and placebo-control study, including 5 sessions of either M1 or "sham" rTMS, a wash-out period (8 weeks), followed by 5 sessions of the other stimulation option (I.e., two arms: M1-sham or sham-M1; order randomized between patients). Treatment efficacy will be assessed in comparison to the placebo condition. Primary outcome is the percentage of pain relief between active and sham rTMS. Other variables to describe quality of life, sensory, neuropathic, and mood states as well as resting-state fMRI will be collected before and after treatment.

02

Conditions studied

  • Cancer
  • Chronic Neuropathic Pain

Keywords

  • Neuropathic pain
  • Cancer
  • Transcranial magnetic stimulation
  • Neuromodulation
  • Pain relief
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient affiliated to or entitled under a social security scheme
  • Patient who has received informed information about the study and who has co-signed, with the investigator, a consent form to participate in the study.
  • Patient aged 18 to 85 (male or female),
  • Central or peripheral neuropathic pain related to cancer and/or its treatment;
  • Chronic pain (present for more than 4 months) whose intensity is greater than or equal to 4/10 on a VAS (Visual Analogue Scale) numerical scale.
  • Pain present on a daily or almost daily basis (at least 4 days a week)
  • Patient not completely relieved by recommended first- and drug treatments for neuropathic pain
  • Stable analgesic treatment (no new treatment or dosage adjustment) for at least one month and will not need to be modified for the duration of the study.
  • Patient can be followed throughout the study.
  • Indication for rTMS of the motor cortex by a neurologist.

Exclusion criteria

Exclusion Criteria:

  • Accident at work or litigation,
  • to rTMS or MRI (treatment with seismotherapy during the previous month; history of cranial trauma; intracranial hypertension; intracerebral metal clip; piercing; pacemaker; insulin pump; metal prosthesis; pregnant or breast-feeding woman; claustrophobia).
  • Chronic alcoholism
  • Abuse of drugs or psychoactive substances
  • Neuropathic pain as part of a progressive pathology (e.g. ),
  • Presence of other pain of greater intensity than the neuropathic pain leading to inclusion
  • Acute stroke (\< 3 months)
  • Patient with brain tumour lesions
  • Patient with infectious or metabolic brain lesions
  • Patients with severe or recent cardiac disorders
  • Patients with cognitive impairment
  • Patient unable to understand ,
  • Patients refusing to stop or unable to stop treatments prohibited during the study, such as morphine.
  • Patients participating in another research protocol involving a medicinal product within 30 days prior to inclusion.
  • Patients deprived of their liberty or under legal protection (guardianship, curatorship, safeguard of justice, family habilitation).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active rTMS - Sham

    5 stimulation sessions on M1 - washout 8 weeks - 5 sham stimulation sessions (placebo-control, same site, inactive stimulation)

    Device: Repetitive transcranial magnetic stimulation (rTMS) - active · Device: Repetitive transcranial magnetic stimulation (rTMS) - inactive

  • Experimental
    Sham - Active rTMS

    5 sham stimulation sessions (placebo-control, same site, inactive stimulation) - washout 8 weeks - 5 stimulation sessions on M1

    Device: Repetitive transcranial magnetic stimulation (rTMS) - active · Device: Repetitive transcranial magnetic stimulation (rTMS) - inactive

Interventions

  • DeviceRepetitive transcranial magnetic stimulation (rTMS) - active

    rTMS session active on the primary motor cortex

  • DeviceRepetitive transcranial magnetic stimulation (rTMS) - inactive

    rTMS session inactive on the primary motor cortex

06

What researchers measure

Primary outcomes

  1. PAIN RELIEF

    PAIN from 0% : no pain relief at all to 100%: completely relief.

    Time frame: Week 7 after the start of RTMs stimulation

Secondary outcomes

  1. Pain Intensity with Visual analog scale (VAS)

    0 no pain to 10 extremely pain

    Time frame: day 7 post RTMs stimulation

  2. score of Neuropathic Pain Symptom Inventory - NPSI

    \[0= zero neuropatthic pain to 100= maximum neuropathic pain\]

    Time frame: day 7 post RTMs stimulation

  3. Brief Pain Inventory - BPI

    1 - 4 = Mild Pain. 5 =Worst Pain Score 6 = Moderate Pain. 7=Worst Pain Score 10 = Severe Pain.

    Time frame: day 7 post RTMs stimulation

  4. Pain relief

    scale ranging from 0% = no relief to 100% = fully relieved

    Time frame: day 7 post RTMs stimulation

  5. Visual Analogic Scale VAS on emotional dimension of pain

    Visual Analogic Scale VAS (0 = not unpleasant) to 10 = extremely unpleasant)

    Time frame: day 7 post RTMs stimulation

  6. Visual Analogic Scale (VAS) on attentional dimension of pain

    0 = does not attract at all to 10 = completely attracts

    Time frame: day 7 post RTMs stimulation

  7. consumption of rescue analgesics

    Time frame: Week 7 after the start of RTMs stimlulation

  8. Effect of rTMS on quality of life

    Quality of life score (EQ-5D) from 0 to 100. 100 corresponds to the best health.

    Time frame: Week 7 after the start of RTMs stimlulation

  9. HADS: Hospital Anxiety and Depression Scale

    from 0 to 14: no anxiety disorders; from 15 to 42: existence of anxiety disorders.

    Time frame: Week 7 after the start of RTMs stimlulation

  10. Tolerance

    Tolerance will be defined as the absence of adverse effects throughout the duration of the protocol, as reported in systematic questionnaires."

    Time frame: week 7 after the start of RTMs stimulation

07

Study locations

1 of 1 sites recruiting
  • PEYRON Roland
    Saint-Etienne, 42055, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2028, 41 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 41 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Sep 22, 2025
StartActual
Jun 13, 2025
Primary completionEst.
Nov 2028
CompletionEst.
May 2029
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07187219
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Jun 13, 2025
Primary completion
Nov 2028 (estimated)
Completion
May 2029 (estimated)
Last update
Sep 22, 2025

Study contacts

Roland PEYRON, PhD
Contact
roland.peyron@chu-st-etienne.fr
0477824095 ext. 33
Roland PEYRON, PhD
principal investigator · Centre Hospitalier Universitaire de Saint Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion